Tom Neyarapally

Tom Neyarapally, Founder and CEO at Archetype Therapeutics, and Mika Newton, a notable figure in healthcare innovation, dive into the revolutionary impact of AI on drug discovery. They discuss how machine learning and real-world data are reshaping treatments and reducing costs. The pair emphasizes the importance of collaboration between AI technology and clinical expertise to speed up therapy development. They also tackle challenges such as data access and the need for personalized medication, showcasing a new era of patient-centered approaches.